James G. Christensen

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Jeffrey W. Clark, A. Iafrate, P. Jänne, 2010, The New England journal of medicine.

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

Jeffrey W. Clark, A. Iafrate, S. Ou, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Crizotinib in ROS 1-Rearranged Non – Small-Cell Lung Cancer

Jeffrey W. Clark, A. Iafrate, A. Shaw, 2014 .

Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion

R. Berkowitz, J. Christensen, R. Salgia, 2007, International Journal of Gynecologic Cancer.